Navigation Links
MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
Date:10/1/2007

nistration may provide the patient with exposure to sirolimus for up to approximately three months.

In addition to safety and tolerability data, the study provided an initial assessment of sirolimus' biological activity in DME. At 45 and 90 days following treatment, patients receiving the two lowest doses of sirolimus by subconjunctival injection demonstrated mean improvements in visual acuity of 8.5 and 7.4 letters over baseline, respectively, using a standard (ETDRS) eye chart. Additionally, this group of patients also experienced anatomical improvements, with a mean decrease in foveal thickness that was consistent with the observed functional improvements in visual acuity. Preliminary data for these patients at 180 days following treatment suggest that these initial improvements in visual acuity and foveal thickness reductions were maintained, or even enhanced, over time in many patients.

"The fact that we are seeing measures of biological activity maintained, and, in some cases improving, through 180 days following a single subconjunctival injection, is somewhat surprising. This finding raises the possibility that sirolimus may be fundamentally changing the course of diabetic retinopathy through its impact on the mTOR (mammalian target of rapamycin) pathway rather than simply reversing macular edema in a more non-specific way," said Dr. Blumenkranz. "Further studies to support or refute this hypothesis will be necessary. However, if so, then the potential clinical utilization of the drug may eventually extend beyond those patients with clinically significant diabetic macular edema."

"The study's findings are intriguing, particularly in light of the fact that a majority of the participants had been previously treated for DME. As such, these results provide great excitement for researchers as we prepare to advance this product into Phase 2 clinical studies," stated David A. Weber, Ph.D., president and chief executive officer of MacuSight. "We are
'/>"/>

SOURCE MacuSight, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 1, 2015 International Isotopes Inc. (OTCQB: ... year ended December 31, 2014.  The Company reports a ... loss, and positive cash flow for the year ended ... in 2014 was approximately $7.5 million compared to approximately ... approximately 10%.  With the exception of the radiological services ...
(Date:4/1/2015)... , April 1, 2015 ... Report on Global Azithromycin Industry and 2015 ... Industry reports added to Pharmaceutical category in ... the report introduces Azithromycin basic information, including ... overview, policy analysis, and news analysis, etc. ...
(Date:4/1/2015)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... Glucose Clamp Study. The study will be performed at ... San Antonio and University Health System,s ... Ralph DeFronzo . The glucose clamp is ...
Breaking Medicine Technology:International Isotopes Inc. Announces 2014 Year End Financial Results 2International Isotopes Inc. Announces 2014 Year End Financial Results 3International Isotopes Inc. Announces 2014 Year End Financial Results 4International Isotopes Inc. Announces 2014 Year End Financial Results 5International Isotopes Inc. Announces 2014 Year End Financial Results 6International Isotopes Inc. Announces 2014 Year End Financial Results 7Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 2Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 3Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 4Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 5Oramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin 2Oramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin 3
... YORK, July 19, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0574348/European-Medical-Displays-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging This research ... market in terms of the challenges faced ...
... drug companies face a number of obstacles to commercialize ... (FDA) and GMP compliance, to distribution agreements and the ... must be coordinated.  Those issues have just become easier ... VPCI have entered into a joint association.  The collaboration ...
Cached Medicine Technology:European Medical Displays Markets 2European Medical Displays Markets 3European Medical Displays Markets 4Spanish Drug Companies Have New Support Option for the U.S. Market 2
(Date:4/1/2015)... Skin cancer is one of the most common ... Forefront Dermatology and Dermatology Associates of Wisconsin want to ensure ... spreads so they are hosting a free skin cancer screening ... 12:30pm. , “If we can see the early warning ... could become cancerous,” said Dr. Ken Katz, who is the ...
(Date:4/1/2015)... April 01, 2015 It is the meat ... breakfast but now found wrapped around other foods, infused into ... been called meat candy, the gateway meat for vegetarians and ... icon, the North American Meat Institute (NAMI) has developed a ... video tour of a bacon processing plant and ...
(Date:4/1/2015)... 2015 Nike Tennis Camps will offer ... girls ages 10-17, providing campers with the opportunity to ... experience all 4 Grand Slam surfaces on 22 courts ... Great Britain’s Davis Cup team and national governing body. ... Park, the National Tennis Centre is the perfect location ...
(Date:4/1/2015)... Fork, UT (PRWEB) April 01, 2015 Pricing ... in the last several months, bring coverage to a third ... in the states of Massachusetts, Kansas, and Iowa, and the first ... An imaging center in Dallas, TX was also added. , In ... Traffic to and general interest in the platform continue to ...
(Date:4/1/2015)... Doctors in Italy have just published research ... against mesothelioma at higher doses. Surviving Mesothelioma has just ... Click here to read it now. , The ... of Siena with unresectable advanced mesothelioma whose ... patients received monthly doses of tremelimumab (instead of every ...
Breaking Medicine News(10 mins):Health News:Forefront Dermatology and Dermatology Associates of Wisconsin Offers Skin Cancer Screenings on April 11th 2Health News:New Ultimate Guide to Bacon Video Provides Inside Look at How Bacon is Made 2Health News:US Sports Camps and Nike Tennis Camps to Launch in London, England this Summer 2Health News:PricingHealthcare.com Adds Facilities in 5 States, Hits 10,000 Monthly Users Milestone 2Health News:PricingHealthcare.com Adds Facilities in 5 States, Hits 10,000 Monthly Users Milestone 3Health News:New Research Finds Immunotherapy Drug May Fight Mesothelioma Better at Higher Doses, According to Surviving Mesothelioma 2
... a specific contact lens solution is very strongly linked to ... ,The study, by University of Illinois researchers, has been ... ,AK is an often severe, aching infection of the ... ,"We began to look for possible contact lens-related ...
... Day, the World Health Organization (WHO) is today launching a ... blood to save the lives of women during and after ... of a broader blood safety agenda redefined in Ottawa this ... blood transfusion in support of the Millennium Development Goals. ...
... Muslim nations are aiming for self-reliance in producing ... said Thursday in Malaysia . Abdullah Ahmad Badawi, ... 57-member Organisation of the Islamic Conference (OIC), said ... of catching infectious diseases.,"Many of these children suffer ...
... Hopkins scientists have discovered proteins present in blood that ... studies of the proteins, CCSA-3 and CCSA-4, suggest they ... identify at-risk individuals. ,"The reality is that ... cancer researcher Robert Getzenberg, Ph.D. "So, ideally we'd like ...
... the University of Edinburgh have shown that hormone therapy can ... hope. ,The study, published today in Clinical ... targeted use of an anti-oestrogen drug could prolong the life ... the use of chemotherapy in others. ,Letrozole hormone ...
... up fast in the West. ,With the tremendous growth ... hundreds of names and numbers stored in its memory but ... belong to the near and dear. ,In case they ... heart attack and the physicians attending on the injured or diseased ...
Cached Medicine News:Health News:Link Between Eye Infections and Contact Lens Use Exposed 2Health News:WHO Intensifies Work on Safe Blood for Mothers 2Health News:WHO Intensifies Work on Safe Blood for Mothers 3Health News:Blood Test Reveals Colon Cancer Proteins 2Health News:Hormone Therapy An Alternative to Chemotherapy for Ovarian Cancer 2Health News:Look Out for ICE in Emergency Situations 2
... VasoSeal VHD was ... rapidly stop bleeding after ... and radiology procedures. It ... sealing device approved for ...
... Surgical Hemostats First Stop absorbable collagen ... that offers superior handling and removal characteristics. ... and tailored to fit the wound. FirstStop ... can easily be peeled away after hemostasis ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
... D-Stat Flowable Hemostat has a ... topical application, such as vascular access ... It is also used as an ... of tissue tracts of femoral access ...
Medicine Products: